Nutriflex Lipid Special Sans Électrolytes (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Valine, together with other essential amino acids in the formulation, is directly delivered into the bloodstream, where it serves as a substrate for protein synthesis, energy production and gluconeogenesis. This helps maintain nitrogen balance and supports tissue repair in patients lacking oral intake.

The prescribed dose is individualized by the treating clinician based on the patient’s weight, metabolic needs and clinical condition. Dosing calculations consider total caloric and protein requirements and are adjusted according to laboratory monitoring.

Use in pregnancy or lactation should be limited to situations where the expected benefit outweighs potential risk. The product is intended for patients unable to receive enteral nutrition, and clinicians should evaluate maternal and fetal considerations before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nutriflex Lipid Special Sans Électrolytes is an electrolyte‑free formulation that focuses on delivering a balanced amino‑acid profile with lipid support. Compared with standard PN emulsions that contain electrolytes, this product may be preferred when electrolyte load must be tightly controlled, such as in renal impairment or specific metabolic conditions.

Store the emulsion at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Inspect the container for any signs of damage before use.

The product is administered intravenously, typically via a central venous catheter, as part of a prescribed parenteral nutrition regimen. Infusion rates are calculated by the clinical team to meet the patient’s caloric and protein targets while monitoring tolerance.

Serious risks include anaphylactic reactions, severe hypertriglyceridaemia, hepatic dysfunction and catheter‑related bloodstream infections. Prompt recognition and management of these events are essential, and patients should be closely monitored throughout therapy.

The product is contraindicated in individuals with known hypersensitivity to any of its components, those with severe hyperlipidaemia, uncontrolled metabolic disorders, or active infections that preclude the use of central venous catheters for infusion.